Numerous studies have demonstrated the ability of HA to target CD44-overexpressing cancer cells [48]; however, it must be remembered that the level of CD44 expression can differ by an order of magnitude depending on the tumor, as we have showed in our study. The gene discussed is CD44; the disease is neoplasm.